In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was $9.86 for the day, down -3.52% from the previous closing price of $10.22. In other words, the price has decreased by -$3.52 from its previous closing price. On the day, 4.71 million shares were traded. GLUE stock price reached its highest trading level at $10.56 during the session, while it also had its lowest trading level at $9.79.
Ratios:
Our analysis of GLUE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.03 and its Current Ratio is at 6.03. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $11.
On January 03, 2023, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $18.
On October 13, 2022, UBS started tracking the stock assigning a Buy rating and target price of $22.UBS initiated its Buy rating on October 13, 2022, with a $22 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 28 ’24 when Versant Venture Capital VI, L. sold 89,990 shares for $9.66 per share. The transaction valued at 869,240 led to the insider holds 2,007,948 shares of the business.
Versant Venture Capital VI, L. sold 67,905 shares of GLUE for $621,801 on Oct 29 ’24. The 10% Owner now owns 1,573,453 shares after completing the transaction at $9.16 per share. On Oct 28 ’24, another insider, Wallace Owen B., who serves as the Officer of the company, bought 20,000 shares for $12.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 605765824 and an Enterprise Value of 407272096. For the stock, the TTM Price-to-Sale (P/S) ratio is 40.47 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 27.197 whereas that against EBITDA is -3.364.
Stock Price History:
Over the past 52 weeks, GLUE has reached a high of $12.40, while it has fallen to a 52-week low of $2.95. The 50-Day Moving Average of the stock is 37.69%, while the 200-Day Moving Average is calculated to be 70.51%.
Shares Statistics:
GLUE traded an average of 2.25M shares per day over the past three months and 863970 shares per day over the past ten days. A total of 61.38M shares are outstanding, with a floating share count of 46.18M. Shares short for GLUE as of 1731628800 were 11152201 with a Short Ratio of 4.95, compared to 1728950400 on 5232009. Therefore, it implies a Short% of Shares Outstanding of 11152201 and a Short% of Float of 33.160000000000004.
